AGIO
Agios Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$40.27+1.65%
Price as of Jul 20, 2026
AGIO ownership
Agios Pharmaceuticals, Inc. ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
1
Net (3m)
-$150.5K
Insider trades by month Buys Sells
Oct
Nov
Jan
Mar
Apr
Jul
Context3-month price +46.3%Institutions mixed (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 10, 2026 | Backstrom Jay T.director | Option | 1,447 | — |
| Jul 10, 2026 | Backstrom Jay T.director | Grant | 1,447 | — |
| Jul 2, 2026 | Gheuens Sarahofficer: Chief Medical Officer | Option | 8,375 | — |
| Jul 2, 2026 | Gheuens Sarahofficer: Chief Medical Officer | Sell | 4,007 | $37.56 |
| Jun 23, 2026 | Ballal Rahul D.director | Option | 2,816 | — |
| Jun 23, 2026 | Burns James Williamofficer: Chief Legal Officer | Grant | 3,000 | — |
| Jun 23, 2026 | FOUSE JACQUALYN Adirector | Grant | 14,950 | $34.16 |
| Jun 23, 2026 | Jones Ceciliaofficer: Chief Financial Officer | Option | 3,000 | — |
| Jun 23, 2026 | Scadden Daviddirector | Grant | 2,927 | — |
| Jun 23, 2026 | Smith Cynthiadirector | Grant | 14,950 | $34.16 |
| Jun 23, 2026 | Milanova Tsvetaofficer: Chief Commercial Officer | Option | 3,000 | — |
| Jun 23, 2026 | Jones Ceciliaofficer: Chief Financial Officer | Grant | 3,000 | — |
| Jun 23, 2026 | CAPELLO JEFFREY Ddirector | Grant | 2,927 | — |
| Jun 23, 2026 | Viswanadhan Krishnanofficer: Chief Strategy and Operations | Option | 3,000 | — |
| Jun 23, 2026 | Backstrom Jay T.director | Grant | 2,927 | — |
| Jun 23, 2026 | Smith Cynthiadirector | Option | 2,816 | — |
| Jun 23, 2026 | Gheuens Sarahofficer: Chief Medical Officer | Option | 3,000 | — |
| Jun 23, 2026 | FOUSE JACQUALYN Adirector | Option | 2,816 | — |
| Jun 23, 2026 | Owen Adams Catherinedirector | Grant | 14,950 | $34.16 |
| Jun 23, 2026 | Ho Maykindirector | Grant | 2,927 | — |
| Jun 23, 2026 | Owen Adams Catherinedirector | Option | 2,816 | — |
| Jun 23, 2026 | Gheuens Sarahofficer: Chief Medical Officer | Grant | 3,000 | — |
| Jun 23, 2026 | Burns James Williamofficer: Chief Legal Officer | Option | 3,000 | — |
| Jun 23, 2026 | Ballal Rahul D.director | Grant | 14,950 | $34.16 |
| Jun 23, 2026 | FOUSE JACQUALYN Adirector | Grant | 2,927 | — |
| Jun 23, 2026 | Scadden Daviddirector | Option | 2,816 | — |
| Jun 23, 2026 | Backstrom Jay T.director | Grant | 14,950 | $34.16 |
| Jun 23, 2026 | Foster-Cheek Kaye Idirector | Grant | 14,950 | $34.16 |
| Jun 23, 2026 | Ballal Rahul D.director | Grant | 2,927 | — |
| Jun 23, 2026 | Goff Briandirector, officer: Chief Executive Officer | Option | 39,000 | — |
Source: AGIO SEC Form 4 filings, latest Jul 10, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their AGIO positions over the last 6 months (SEC Form 13F).
Increased
176
New positions
91
Reduced
152
Sold out
84
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | Reduced | 5.9M | May 15, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Increased | 5.8M | Feb 17, 2026 |
| BLACKROCK, INC. | Increased | 5.8M | May 13, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Increased | 5.7M | May 15, 2026 |
| VANGUARD GROUP INC | Reduced | 5.6M | Jan 29, 2026 |
| BLACKROCK, INC. | Increased | 5.2M | Feb 12, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Reduced | 5.2M | Feb 17, 2026 |
| STATE STREET CORP | Increased | 3.4M | May 15, 2026 |
| STATE STREET CORP | Increased | 3.1M | Feb 13, 2026 |
| ARMISTICE CAPITAL, LLC | Increased | 3.0M | Feb 17, 2026 |
| ERSTE ASSET MANAGEMENT GMBH | Increased | 2.8M | Feb 11, 2026 |
| ERSTE ASSET MANAGEMENT GMBH | Reduced | 2.7M | May 11, 2026 |
| D. E. SHAW & CO., INC. | Increased | 2.7M | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 2.6M | May 15, 2026 |
| LYNX1 CAPITAL MANAGEMENT LP | Increased | 2.6M | May 4, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.